Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound Successfully Completes Second Cohort of EscharEx® Phase 2 Study
Company intends to initiate EscharEx U.S. pivotal program in first half of 2018
View HTML
Toggle Summary MediWound Reports Second Quarter 2017 Financial Results
NexoBrid ® sales double in first half of 2017 BARDA upsizes committed funding by additional $32 million , bringing total contract value to up to $132 million of non-dilutive financing Conference call begins today at 8:30 a.m. Eastern time YAVNE, Israel , Aug.
View HTML
Toggle Summary MediWound to Host Second Quarter 2017 Financial Results Conference Call on August 3, 2017 at 8:30 a.m. Eastern Time
YAVNE, Israel , July 28, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the six
View HTML
Toggle Summary BARDA Upsizes Contract with MediWound and Exercises Option to Fund Further NexoBrid® Indications
Commits an Additional $32 Million to Support R&D Activities, Brings Total Non-Dilutive Funding to Up to $132 Million
View HTML
Toggle Summary BARDA Gives Notice of Intent to Exercise First Contract Option to Further Fund MediWound's NexoBrid® Development
YAVNE, Israel , June 23, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that it received from the U.S.
View HTML
Toggle Summary Independent Study in Germany Shows NexoBrid® Reduces Average Burn Treatment Costs by nearly 30% Versus Standard of Care
Findings published in peer-reviewed journal
View HTML
Toggle Summary MediWound to Present at the Jefferies Global Healthcare Conference
YAVNE, Israel , June 05, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that management will participate at the Jefferies 2017 Global Healthcare
View HTML
Toggle Summary Poster Presentation Highlighting NexoBrid® Awarded "Best Poster" at the 52nd Congress of the Spanish Society of Aesthetic, Plastic and Reconstructive Surgery
Award-winning Abstract Underscores Role of NexoBrid in the Treatment of Severely Burned Hands
View HTML
Toggle Summary MediWound Announces Changes to its Board of Directors
YAVNE, Israel, May 18, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the Board of Directors has appointed Vickie R. Driver, DPM and Stephen T. Wills, CPA to its Board of Directors, effectiv...
View HTML
Toggle Summary MediWound Reports First Quarter 2017 Financial Results
YAVNE, Israel, May 08, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three months ended March 31, 2017. Highlights of the first quarter of 2017 and recent weeks includ...
View HTML